Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | ALPL | P05186 | 10/20 | 0.57 |
| ▸ | ACLY | P53396 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3454061 | 0.83 | ALDH1A1 (0.63) | ALDH1A1ALPLKMT2ATP53TDP1 | |
| SCHEMBL3717535 | 0.77 | ALDH1A1 (0.62) | ALDH1A1ALPLKMT2ATP53TDP1 | |
| SCHEMBL3454118 | 0.76 | KMT2A (0.55) | ALDH1A1ALPLKMT2ATP53TDP1 | |
| SCHEMBL31371215 | 0.71 | ALPL (1.00) | ALDH1A1ALPLLMNAGAA | |
| SCHEMBL15211944 | 0.71 | ALPL (1.00) | ALDH1A1ALPLLMNAGAA | |
| SCHEMBL8130432 | 0.71 | LMNA (0.56) | ALDH1A1KMT2ATDP1LMNA | |
| SCHEMBL21999615 | 0.71 | ACLY (1.00) | ALPLACLYPGR | |
| SCHEMBL5802392 | 0.70 | PGR (0.68) | ALDH1A1KMT2APGR | |
| SCHEMBL15212089 | 0.70 | ALDH1A1 (0.76) | ALDH1A1ALPLKMT2ATP53TDP1 | |
| SCHEMBL1471379 | 0.69 | AR (0.59) | ALDH1A1TDP1CYP3A4PPARGLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816382-B2 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070004677-A1 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004677-A1 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | P2RY1, P2RY11, UTS2R | ALDH1A1 2767/4885ALPL 4273/4885ACLY 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.